Table 1 Patients’ demographics and clinical characteristics (N = 112)¹

Marital status

Single

15 (13.4%)

Married

94 (83.9%)

Widowed

3 (2.7%)

Presence of metastases²

No

104 (92.9%)

Yes

8 (7.1%)

Type of metastases²

Bone

6 (75%)

Lung

2 (25%)

Type of chemotherapy²

Adjuvant

79 (71.2%)

Neoadjuvant

24 (21.6%)

Palliative

8 (7.2%)

Mean ± Standard Deviation (SD)

Median [25–75 Percentiles]³

Age (years)

56.04 ± 11.69

56 [49–65]

Body Mass Index (BMI; Kg/m²)

25.90 ± 4.62

25.65 [23.46–28.14]

Body Surface Area (BSA; m²)

1.75 ± 0.16

1.74 [1.66–1.86]

Number of chemotherapy cycles

4.45 ± 2.35

4 [2–6]

Pain VAS score

1.68 ± 2.49

0 [0–3]

Cognition⁴

  CogPCI score

56.94 ± 14.29

58.5 [49–67]

  CogPCA score

22.99 ± 5.55

24 [20–26]

  CogOTH score

13.28 ± 3.17

14 [12–16]

  CogQOL score

10.02 ± 4.79

10 [6–14.75]

  Total FACT-Cog score

103.25 ± 23.15

107 [95–119]

Sleep evaluation⁴

  Insomnia Severity Index (ISI) score

10.44 ± 7.19

9 [5–15.75]

  Pittsburgh Sleep Quality Index (PSQI) score

8.91 ± 4.63

9 [5–12]

Psychological factors⁴

  HADS-A

8.69 ± 5.25

9 [4–13]

  HADS-D

7.27 ± 4.59

7 [3–11]

Fatigue Score⁴

42.12 ± 32.10

33.33 [11.11–66.67]